Foliglurax monohydrochloride is primarily investigated for its potential therapeutic applications in neurological disorders. It acts as a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), which plays a role in regulating neurotransmitter release and synaptic plasticity. This mechanism makes it a promising candidate for treating conditions such as Parkinson’s disease, where mGluR4 modulation can help alleviate motor symptoms by enhancing dopamine signaling and reducing excitotoxicity. Additionally, its neuroprotective properties are being explored for potential use in other neurodegenerative diseases, offering hope for slowing disease progression and improving patient outcomes. Research is ongoing to fully understand its efficacy and safety in clinical settings.